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In search of an affinity label of the opioid receptor, the nitrogen mustard melphalan, Mel, was built into 
the peptide chain of D-AlaZ-LeuS-enkephalin (DALE) methyl ester in different positions. We report now 
that in contrast to the previous observations that an intact Tyr in position 1 is essential for opioid activity 
[(1980) Annu. Rev. Pharmacol. Toxicol. 20, 81-l lo], substitution of Tyr by Mel did not result in a loss 
of the binding affinity. Mel’, Leus-enkephalin-OMe competed for the binding sites of [3H]naloxone as po- 
tently as DALE did; IC,, values for both compounds were 50 nM. Mel substitution has led to one order 
potency decrease in binding to the b-sites. 0.5-l PM of the compound irreversibly inactivates 50% of the 
binding sites of [3H]naloxone, and 5-10 ,uM of that of [3H]DALE. These results hed new light on the struc- 
tural requirements e tablished for opioid peptides. In addition, the new derivative can be used as an affinity 
label of the opioid receptor. 
Opioid receptor New enkephalin analog Affinity labeling 
1. INTRODUCTION properties des-Tyr-&casomorphin shows no affini- 
ty to the p-receptor [5]. 
Since the discovery of the enkephalins as natur- 
ally occurring ligands of opioid receptors [2], hun- 
dreds of analogues have been synthesized. These 
studies have led to the conclusion that an intact 
tyrosyl residue at the N-terminus is essential for 
significant opioid activity [ 11. Thus, its substitu- 
tion by tryptophan, phenylalanine, or dopa-dihy- 
droxyphenylalanine results in a loss of binding af- 
finities of 2 or 3 orders of magnitude [3]. More 
precisely, the aromatic hydroxyl group of tyrosine 
seems essential, and its removal [3], or replacement 
by a p-amino, -nitro, -chloro, or -iodo group [l] 
leads to large affinity losses. To date, the only ex- 
ception was a cyclic enkephalin analogue, Phe- 
c(-N’-D-Lys-Gly-Phe-Leu-), which showed twice 
the potency of Leu-enkephalin in the GPI assay 
141. The same substitution in the linear analogue 
resulted in a drastic reduction in potency [4]. An 
intact Tyr seems to be important for casomor- 
phins, the other peptide family with morphine-like 
In search of a potent affinity label for the opiate 
receptor, the nitrogen mustard melphalan (Cbis/ 
-3-chloro-ethyl/-amino-L-phenylalanine), Mel, was 
coupled to the C-terminal end of D-Ala’-Leu’- 
enkephalin [6]. The compound, DALA-Mel-OMe, 
was shown to bind with high affinity and irrever- 
sibly to rat brain opioid receptors [6]. We report 
now that substitution of the N-terminal Tyr for 
melphalan results in a highly active enkephalin 
analogue. Moreover, as an affinity label it might 
provide a valuable tool for characterizing the in- 
teraction of opioid ligands with their respective 
receptor size. 
2. MATERIALS AND METHODS 
2.1. Synthesis of Mel-D-Ala-Gly-Phe-Leu-OMe 
(Mel’, Leu’-enkephalin-OMe) 
Boc-protected melphalan was coupled to H-D- 
Ala-Gly-Phe-Leu-OMe with the aid of i-butyl- 
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chlorocarbonate in the presence of N-methylmor- 
pholine. Boc was removed from the pentapeptide 
by HCI in formic acid. The purity of the peptide 
was checked by amino acid analysis and by TLC. 
The ionic and covalent chloro content of the com- 
pound was also determined. Details of the syn- 
thesis will be described elsewhere. 
2.2. Rat brain membrane preparation 
Rat brain membranes were prepared according 
to [7]. Briefly, brains (without cerebella) were 
homogenized in 30 vols of 50 mM Tris-HCl (pH 
7.4) buffer by a Teflon potter. After filtration 
through gauze, the homogenate was pelleted at 
40 000 x g for 20 min. The pellet, suspended in the 
original volume of buffer, was incubated at 37°C 
for 30 min, then recentrifuged. The final pellet was 
suspended in 5 vols (for affinity labeling) or 80 vols 
(for displacement studies) of 50 mM Tris-HCl (pH 
7.4). 
2.3. Affinity labeling 
The reaction mixture contained 200 ~1 of the 
ligand at the appropriate concentration, 100 pl 
ethanol, 50 mM Tris-HCl (pH 7.4) and 500~1 of 5 
vols rat brain membranes in a final volume of 2 ml. 
After 120 min incubation at 3O”C, samples were 
diluted with 28 ml of 4°C Tris-HCl buffer and cen- 
trifuged at 25 000 x g for 10 min. The pellets were 
suspended in 30 ml buffer, incubated for 10 min at 
room temperature and centrifuged again. This 
washing step was repeated 4 times. The final pellets 
were homogenized in 8 ml of 50 mM Tris-HCI (pH 
7.4) buffer and used immediately for binding 
assay. 
2.4. Binding assay 
To assess the binding affinity of the compounds, 
800~1 of rat brain membrane preparation (400-800 
pg protein) was co-incubated with different con- 
centrations of the ligands and 0.5 nM [7,8,9,20- 
‘Hlnaloxone (spec. act. 83.7 Ci/mmol), [8] or 1 
nM [3,5-3H-Tyr]‘D-Ala2-Leu5-enkephalin (spec. 
act. 32.3 Ci/mmol) (Benyhe et al. submitted) in 50 
mM Tris-HCl (pH 7.4) in a final volume of 1 ml. 
The reaction was continued for 1 h at 4°C for 
[3H]naloxone and for 45 min at 23°C for [3H]- 
DALE binding and was stopped by filtration 
through Whatman GF/B or GF/C filters, respec- 
tively. Non-specific binding was measured with 10 
PM unlabeled naloxone or 100pM DALE and sub- 
tracted from total binding. Only specific binding is 
reported. 
In the binding assay after affinity labeling, 800 
~1 of pretreated membrane preparation (200-350 
pg protein) was incubated with 0.5 nM [3H]nalox- 
one or 1 nM [3H]DALE and continued as above. 
The protein content was determined as in [9]. 
3. RESULTS 
Surprisingly, substitution of Tyr for melphalan 
in position 1 resulted in a compound with high af- 
finity to rat brain opioid receptors (fig. 1). The new 
bN~Ll~ANDl.tN, loa ILIaAND1.w 
Fig. 1. Competition of Mel-D-Ala-Gly-Phe-Leu-OMe for rat brain opioid receptors (A) 800 pl of rat brain membranes 
were incubated with 0.5 nM [3H]naloxone and competing ligands for 1 h at 4°C and specific binding was determined. 
(B) Competition curve with 1 nM [3H]DALE after 45 min incubation at 23°C. (x) Naloxone, (0) DALE, (0) 
Me11,Leu5-enk.-OMe. One representative xperiment of 3 others, each measured in duplicate. 
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Fig.2. Concentration dependence of irreversible interaction of opioid receptors by Mel’,Leu’-enk.-OMe. Rat brain 
membranes were incubated with various concentrations of Mel’,Leu’-enk.-OMe for 120 min at 30°C for (A) and for 
90 min for (B) in a final volume of 2 ml in 50 mM Tris-HCl (pH 7.4) buffer. After 4 washes, the remaining binding 
was measured with (A) 0.5 nM [3H] naloxone after an additional 1 h incubation at 4”C, and (B) 1 nM [3H]DALE after 
2 h incubation at 4°C. Remaining specific binding was normalized by protein concentration and expressed as percentage 
of control binding (preincubation in buffer and 4 washes). 
compound, Mel’-Leu’-enkephalin-OMe has the 
same affinity as the parent compound, DALE, for 
the binding sites of [3H]naloxone (KSO = 5 x lo-* 
M), and shows a somewhat lower affinity (IGO = 
1 x lo-* M) than DALE (I& = 1.5 x 10e9 M) for 
the binding sites of t3H]DALE. 
The irreversible binding of Mel’,Leu’-enke- 
phalin-OMe was tested with [3H]naloxone (which, 
under the circumstances described, labels mainlyp- 
sites) and with [3H]DALE (which labels mainly I.% 
sites) to membranes preincubated with the com- 
pound. As shown in fig.2, Mel’,Leu’-enkephalin- 
OMe caused a dose-dependent irreversible block- 
ade of both binding sites. Me11,Leu5-enkephalin- 
OMe blocked 50% of the [3H]naloxone sites at 
0.5-l pM and caused 93% inhibition at 100 pM. 
On the other hand, it was less active in irreversibly 
inactivating the &sites, having an IGO of 5-10,uM. 
To determine the efficiency of the washing pro- 
cedure, membranes were preincubated with the 
reversible opioid ligands, naloxone and DALE. A 
complete restoration of the binding was observed 
after 4 washes (not shown). Melphalan itself, at 50 
,uM, did not cause any inhibition [6]. 
To determine the specificity of labeling, mem- 
branes were pretreated with naloxone or DALE 
Table 1 
Protection of naloxone binding sites 
Treatment Specific [‘Hlnaloxone binding 
dpm . mg % of 
control 
protein-’ 
Control 3111 100 
Mel’,Leu’-enk.-OMe 
(50 /cM) 318 10 
Mel’,Leu’-enk.-OMe 
(50pM) + naloxone 
(100 PM) 964 32 
Mel’,Leu’-enk.-OMe 
(50pM) + DALE 
(100 PM) 894 29 
Naloxone and DALE were added 10 min before 
Mel’,Led-enk.-OMe to rat brain membranes. After 120 
min of further incubation at 3O”C, the membranes were 
washed by 4 centrifugation/resuspension steps and the 
remaining specific binding was measured with 0.5 nM 
[3H]naloxone in quadruplicate. Control samples were 
run under identical conditions, substituting buffer for 
the ligand. Results are the average of two parallel in- 
cubations 
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before the addition of Mel’,Leu’-enkephalin- 
OMe. The opioid added first should occupy the 
receptors, thus protecting them from inactivation 
by Mell,Leus-enkephalin-OMe. As shown in table, 
only partial protection was achieved under the 
reaction conditions applied. 50 ,uM Mel’,Leu’-en- 
kephalin-OMe caused 90% inhibition, which 
decreased to 70% when naloxone or DALE was 
given first. 
4. DISCUSSION 
A new analogue of D-Ala’-Leu’-enkephalin was 
synthesized and tested for its in vitro binding ac- 
tivity. The compound, Me11,Leu5-enkeph~in-OMe 
competed with high affinity for both ]‘H]naloxone 
and t3H]DALE binding sites. Thus, the generally 
accepted rule, that an intact Tyr residue is neces- 
sary for opioid activity, has to be reconsidered. 
The fundamental role of Tyr was explained such 
[lo] that the benzene ring of morphine which bears 
a hydroxyl group is in precisely the same orienta- 
tion as the benzene ring of tyrosine, suggesting that 
this group binds to the opioid receptor in both 
cases. Conformational reasons might cause the ex- 
traordinary property of melphalan, which allow 
retainment of opioid activity upon replacing Tyr. 
The chloroethylamino group in the para position 
of phenylalanine might induce a conformational 
change of the peptide which then fits to the recep- 
tor. It is not a suprise, on the other hand, that 
melphalan substitution resulted in a compound 
which is able to bind irreversibly to the receptor, 
melphalan being a well-known alkylating agent. 
We have found that other analogues of D-Ala2- 
Let.?-enkephalin containing melphalan in different 
positions of the peptide chain are also able to bind 
irreversibly to the opioid receptor (submitted). Ex- 
periments are in progress to elucidate the mechan- 
ism of Mel’,Leu’-enkephalin-OMe binding. 
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